Mubadala and G42 group have partnered to start a biopharmaceutical manufacturing plant in Abu Dhabi.
The facility will invest in and establish multiple initiatives, leveraging the expertise of Mubadala’s advanced manufacturing companies as well as G42’s capabilities in artificial intelligence and cloud computing.
The agreement promotes advances in the UAE’s socio-economic growth and diversification while also improving health outcomes across the nation and the wider Middle East region.
Global supply shortages have resulted in biopharmaceuticals becoming a high growth market with a 10 per cent compound annual growth rate (CAGR) over the past five years and have become a priority investment area for Mubadala within the life sciences sector.
The ability of biopharmaceutical products to address previously untreatable conditions has also inspired confidence in the market’s long-term and future growth potential.
US court rules Meta, other tech firms must face thousands of social media addiction lawsuits
US judge dismisses criminal case against Indian billionaire Adani
Abu Dhabi and Dubai explore seamless parking integration
Global Village opens registration for F&B outlets
UAE advances agentic AI project targeting 50% of government operations
